Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
![]() |
MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright...
Read more: Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference





